Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy

Blood

Volumn 111, Issue 4, 2008, Pages 1816-1819

  O'Brien, Susan ^a   Ravandi, Farhad ^a   Riehl, Todd ^a   Wierda, William ^a   Huang, Xuelin ^a   Tarrand, Jeffrey ^a   O'Neal, Brandi ^a   Kantarjian, Hagop ^a   Keating, Michael ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ASPARAGINASE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; FOSCARNET; GANCICLOVIR; METHOTREXATE; PENTOSTATIN; RITUXIMAB; VALACICLOVIR; VALGANCICLOVIR; VINCRISTINE;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; HAIRY CELL LEUKEMIA; HERPES VIRUS; HUMAN; INFECTION PREVENTION; MONOTHERAPY; NEUTROPENIA; NONHUMAN; PNEUMOCYSTIS CARINII; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS REACTIVATION;

EID: 41349087090     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-03-080010     Document Type: Article

References (13)

1. Ravandi F, O'Brien S. Alemtuzumab. Expert Rev Anticancer Ther. 2006;5:39-51.
2. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554-3561.
3. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768-773.
4. Nguyen DD, Cao TM, Dugan K, Starcher SA, Fechter RL, Coutre SE. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma. 2002;3:105-110.
5. Laurenti L, Piccioni P, Cattani P, et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica. 2004;89:1248-1252.
6. Ferrajoli A, O'Brien SM, Cortes JE, et al. Phae II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003;98:773-778.
7. Fraser GA, Walker II. Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood and Marrow Transplantation guideline recommendations. Biol Blood Marrow Transplant. 2004;10:287-297.
8. Curran M, Noble S. Valganciclovir. Drugs. 2001;61:1145-1150.
9. Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med. 2002;346:1119-1126.
10. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leucemia alter alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23:2971-2979.
11. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leucemia patients who also had received fludarabine. J Clin Oncol. 2002;20:3891-3897.
12. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia: European study group of CAMPATH-1H Treatment in chronic lymphocytic leukemia. J Clin Oncol. 1997;15:1567-1574.
13. Mackus WJ, Frakking FN, Grummels A, et al. Expansion of CMV-specific CD8+CD45RA+CD27-T cells in B-cell chronic lymphocytic leukemia. Blood. 2003;102:1057-1063.